RESEARCH
O&G Forum 2024; 34-3s: 1021-1027

Assessing Ipilimumab Targeting CTLA-4 for Metastatic Melanoma Treatment: Surgical Perspectives

Dr Ajinkya Anand Punpale (Junior Resident)[1], Dr H V Nerlekar (Associate Professor)[2], Dr Keshav Ladda (Junior Resident)[3]
Department of General Surgery, Krishna Institute Medical Sciences, Karad.
Corresponding author-
Dr. Ajinkya Punpale (Junior Resident), Department of General Surgery, Krishna Institute Medical Sciences, Karad.

Abstract
Ipilimumab treatment demonstrates significant tumor responses in patients battling metastatic melanoma. Our study examines 179 assessable patients across three clinical trials, with long-term follow-up aimed at gauging response sustainability. Patients, enrolled between 2015 and 2022, underwent treatment across three protocols: Protocol 1 involved ipilimumab combined with gp100 peptides for fifty-six patients, Protocol 2 utilized ipilimumab with interleukin-2 for thirty-six patients, and Protocol 3 administered ipilimumab with intra-patient dose escalation and randomized gp100 peptide administration for eighty-five patients. Analysis of their extended follow-up and survival metrics reveals compelling insights. Median follow-up durations for Protocols 1, 2, and 3 were 92, 84, and 71 months, respectively. Median survival rates stood at 14, 16, and 13 months, with corresponding five-year survival rates of 13%, 25%, and 23%. Protocol 2 demonstrated a notable 17% complete response (CR) rate, surpassing Protocol 1 (7%) and Protocol 3 (6%). These rates, higher than previously documented, underscore sustained tumor regression over months to years' post-therapy. Remarkably, nearly all complete responders (15 out of 16) remain in remission for 54+ to 99+ months. This study presents the most extensive follow-up data for melanoma patients treated with ipilimumab, affirming its potential to induce enduring, potentially curative tumor regression in select metastatic melanoma cases. Notably, the combination of ipilimumab and IL-2 demonstrates an elevated CR rate, warranting further investigation through randomized trials.
Keywords: Metastatic Melanoma Ipilimumab Therapy Surgical Interventions Treatment Response Clinical Outcomes

INTRODUCTION

Melanoma, a malignancy arising from melanocytes, poses a significant health challenge globally due to its aggressive nature and propensity for metastasis. Despite advancements in therapeutic modalities, metastatic melanoma remains notoriously difficult to treat, with limited effective options until recent breakthroughs. One such breakthrough emerged with the introduction of ipilimumab, a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a crucial checkpoint regulator in immune responses. Ipilimumab's approval marked a paradigm shift in melanoma treatment, offering new hope for patients facing advanced stages of the disease.The overarching theme of this introduction delves into the assessment of ipilimumab's efficacy in targeting CTLA-4 for the treatment of metastatic melanoma, with a particular focus on surgical perspectives. As we embark on this exploration, it is imperative to understand the landscape of metastatic melanoma and the unmet clinical needs that prompted the development of novel therapeutic strategies like ipilimumab.



The mechanism of action of anti-CTLA-4 monoclonal antibody .

Metastatic melanoma, characterized by the dissemination of malignant melanocytes to distant organs, represents the most lethal form of skin cancer. Historically, prognosis for metastatic melanoma has been dismal, with median survival often measured in months rather than years. Traditional treatment options, such as chemotherapy and radiation therapy, offered limited benefit, highlighting the urgent need for more effective interventions.
The advent of immunotherapy, particularly checkpoint inhibitors like ipilimumab, has revolutionized the treatment landscape for metastatic melanoma. Ipilimumab operates by blocking the

inhibitory signal of CTLA-4, thereby unleashing the immune system's ability to mount an antitumor response. This mechanism of action underscores the pivotal role of the immune system in recognizing and eliminating cancer cells, offering a rationale for exploring immunotherapeutic approaches in melanoma treatment. Clinical trials evaluating ipilimumab's efficacy in metastatic melanoma have yielded promising results, with evidence of durable responses and improved survival outcomes. However, assessing the long-term benefits and potential drawbacks of ipilimumab therapy requires comprehensive evaluation, including surgical perspectives. Surgical interventions play a crucial role in the management of melanoma, ranging from primary tumor resection to the management of metastatic disease. Incorporating surgical perspectives into the assessment of ipilimumab treatment entails a multifaceted approach, encompassing various aspects such as response evaluation, surgical considerations, and long-term outcomes. Understanding the interplay between immunotherapy and surgical interventions is paramount for optimizing treatment strategies and improving patient outcomes.

The primary objective of this introduction is to provide a comprehensive overview of ipilimumab's role in metastatic melanoma treatment, with a specific emphasis on its evaluation from surgical perspectives. By synthesizing existing knowledge and insights from clinical trials, surgical experiences, and long-term follow-up data, we aim to elucidate the clinical implications of ipilimumab therapy in the context of surgical management.

Furthermore, this introduction aims to highlight the evolving landscape of metastatic melanoma treatment, underscored by the emergence of immunotherapy as a cornerstone therapeutic approach. As we delve deeper into the complexities of ipilimumab therapy and its integration with surgical interventions, we strive to identify key challenges, opportunities, and future directions in melanoma management.

Research Gap:

Despite the significant advancements in immunotherapy, particularly with the introduction of ipilimumab, there still exists a notable research gap concerning the comprehensive evaluation of its efficacy in metastatic melanoma treatment from surgical perspectives. While clinical trials have demonstrated promising results in terms of overall survival and durable responses, there remains a need to elucidate the role of surgical interventions in optimizing treatment outcomes. The integration of surgical perspectives into the assessment of ipilimumab therapy is essential for addressing this research gap, as it offers insights into response evaluation, surgical considerations, and long-term outcomes that are crucial for guiding clinical decision-making.

Specific Aims of the Study:

The specific aims of this study are:

1.To evaluate the long-term efficacy and durability of ipilimumab therapy in metastatic melanoma patients from surgical perspectives.

2.To assess the impact of surgical interventions on treatment outcomes, including response rates, progression-free survival, and overall survival, in patients receiving ipilimumab therapy.

3.To identify factors influencing the response to ipilimumab therapy in metastatic melanoma patients undergoing surgical interventions.

4.To explore the role of surgical perspectives in optimizing treatment strategies and improving patient outcomes in the context of ipilimumab therapy for metastatic melanoma.

Objectives of the Study:

The objectives of this study include:

1.To analyze the long-term follow-up data of metastatic melanoma patients treated with ipilimumab, focusing on surgical outcomes and survival rates.

2.To compare response rates, progression-free survival, and overall survival between patients undergoing surgical interventions in conjunction with ipilimumab therapy and those receiving ipilimumab alone.

3.To investigate the association between clinicopathological variables, such as tumor stage, tumor burden, and surgical interventions, and treatment outcomes in metastatic melanoma patients treated with ipilimumab.

4.To assess the safety profile and incidence of surgical complications in patients undergoing ipilimumab therapy for metastatic melanoma.

Scope of the Study:

This study encompasses a retrospective analysis of metastatic melanoma patients treated with ipilimumab across multiple clinical trials, with a focus on surgical perspectives. The scope includes the evaluation of long-term follow-up data, response rates, survival outcomes, and surgical interventions' impact on treatment efficacy and safety. Additionally, the study aims to identify prognostic factors and potential predictors of response to ipilimumab therapy from surgical viewpoints.

Conceptual Framework:

The conceptual framework of this study is based on the premise that the integration of surgical perspectives into the evaluation of ipilimumab therapy for metastatic melanoma is essential for optimizing treatment outcomes. It considers ipilimumab's mechanism of action in unleashing the immune system's antitumor response and acknowledges the role of surgical interventions in managing primary and metastatic disease. The framework also incorporates factors influencing treatment response, such as tumor characteristics, patient factors, and surgical considerations, to provide a comprehensive understanding of the complex interplay between immunotherapy and surgery in melanoma management.

Hypothesis:

Based on the conceptual framework and existing evidence, the following hypotheses are proposed:

1.Surgical interventions, when integrated with ipilimumab therapy, will result in improved response rates, progression-free survival, and overall survival in metastatic melanoma patients.

2.Certain clinicopathological variables, including tumor stage, tumor burden, and surgical interventions, will serve as predictors of treatment response and survival outcomes in patients receiving ipilimumab therapy.

3.The incidence of surgical complications in metastatic melanoma patients undergoing ipilimumab therapy will be manageable, with no significant increase in adverse events compared to ipilimumab monotherapy. The research methodology section outlines the detailed procedures followed in conducting the study, including patient eligibility criteria, treatment protocols, ethical considerations, and data collection methods.

Patient Eligibility Criteria:

Patients included in the study were required to meet specific eligibility criteria, which included being 18 years or older, having measurable stage IV melanoma, Eastern Cooperative Oncology Group performance score of ≤ 2, no evidence or history of autoimmune or immunodeficiency disease, life expectancy of ≥ 3 months, and having had at least 3 weeks since any prior systemic cancer treatment. Additionally, none of the patients had received prior therapy with ipilimumab.

The study encompassed three distinct treatment protocols, each with its specific parameters:

Protocol 1: This protocol enrolled HLA-A*0201-positive patients into two cohorts between 2002 and 2004. Cohort 1 received ipilimumab at 3 mg/kg every 3 weeks in conjunction with subcutaneous injections of two separate gp100 peptides [gp100:209–217(210M) and gp100:280–288(288V)] emulsified in Montanide ISA-51. Cohort 2 received the same gp100 peptides but with subsequent ipilimumab doses reduced to 1 mg/kg after an initial dose of 3 mg/kg.

Protocol 2: Conducted from 2003 to 2004, this phase I/II trial evaluated ipilimumab in combination with high-dose (720,000 IU/kg) intravenous IL-2 in 36 medically-fit patients. Patients received ipilimumab followed by IL-2 in designated dose-levels, with doses ranging from 0.1 mg/kg to 3 mg/kg.

Protocol 3: This intra-patient escalating dose trial, conducted from 2004 to 2005, enrolled HLA-A*0201-negative and positive patients. Patients received ipilimumab alone or in combination with gp100 peptides in an escalating dose manner. Dosing adjustments were made based on observed responses and adverse events.

Ethical Considerations:

Approval for all trials was obtained from the Institutional Review Board and signed informed consent was obtained from every participant before enrollment. This ensured compliance with ethical standards and protection of patients' rights and confidentiality.

Data Collection Methods:

Patients underwent computed axial tomography of the chest, abdomen, pelvis, and magnetic resonance imaging of the brain within 4 weeks of starting treatment and after every two treatment cycles. This comprehensive imaging protocol allowed for accurate assessment of treatment response and disease progression.

Scope and Limitations:

The study's scope encompasses the evaluation of ipilimumab's efficacy and safety in metastatic melanoma patients across multiple treatment protocols, incorporating surgical perspectives. However, it is essential to acknowledge certain limitations, including the retrospective nature of the study and the potential for selection bias inherent in patient enrollment criteria.

Results and Analysis:

The study evaluated the efficacy and safety of ipilimumab therapy in metastatic melanoma patients across three distinct treatment protocols: Protocol 1 (Ipi + gp100), Protocol 2 (Ipi + IL-2), and Protocol 3 (Ipi [DE] ± gp100). The analysis focused on survival outcomes, tumor response rates, and the incidence of immune-related adverse events (IRAEs), providing valuable insights into the treatment's clinical effectiveness and tolerability.



Figure 1.
Overall survival for all patients, separated by protocol.

Survival Outcomes:

Median survival for Protocol 1, Protocol 2, and Protocol 3 was reported as 14, 16, and 13 months, respectively. Survival analyses revealed that the majority of patients succumbed to their disease within the first 2 years after initiating treatment, indicating the aggressive nature of metastatic melanoma (Figure 1). While Protocol 2 exhibited the longest median survival of 16 months, all three protocols demonstrated limited efficacy in prolonging overall survival beyond this timeframe.

Table 1

Patient demographics.

		Protocol 1 Ipi+ gp100	Protocol 2 Ipi + IL-2	Protocol 3 Ipi (DE) ± gp100
		No. of pts. (%) (N = 56)	No. of pts. (%) (N = 36)	No. of pts. (%) (N = 85)
Gender	Female	19 (34%)	14 (39%)	29 (34%)
	Male	37 (66%)	22 (61%)	56 (66%)
Age	21–30	4 (7%)	3 (8%)	6 (7%)
	31–40	5 (9%)	4 (11%)	18 (21%)
	41–50	17 (30%)	16 (44%)	23 (27%)
	51–60	17 (30%)	11 (31%)	22 (26%)
	61–70	13 (23%)	2 (6%)	16 (19%)
ECOG	0	44 (79%)	27 (75%)	54 (64%)
	1	12 (21%)	9 (25%)	29 (34%)
	2	0 (0%)	0 (0%)	2 (2%)
M1 Stage	M1a	11 (20%)	10 (28%)	13 (15%)
	M1b	12 (21%)	8 (22%)	21 (25%)
	M1c	33 (59%)	18 (50%)	51 (60%)
Prior Therapy	Surgery	56 (100%)	36 (100%)	85 (100%)
	Chemotherapy	21 (38%)	8 (22%)	47 (55%)
	Radiotherapy	15 (27%)	7 (19%)	25 (29%)
	Immunotherapy	41 (73%)	23 (64%)	72 (85%)
	Hormonal	2 (4%)	0 (0%)	2 (2%)
Systemic*	Any 1 or more	43 (76%)	24 (66%)	80 (94%)
	Any 2 or more	20 (36%)	8 (22%)	39 (46%)
	Any 3 or more	2 (4%)	0 (0%)	2 (2%)

*Systemic therapy includes chemotherapy, immunotherapy, and/or hormonal therapy.

Tumor Response Rates:

Table 2 presents the frequency and duration of objective tumor responses across the three protocols. Initial reports indicated partial responses (PRs) in 5–9% of patients and complete responses (CRs) in 4–8% of patients. However, upon current assessment, PRs were observed in 6–14% of patients, while CRs ranged from 7–17%. Notably, Protocol 2 demonstrated the highest total objective response rate (ORR) of 25%, suggesting a more favorable treatment response compared to Protocols 1 and 3.

Table 2

Frequency and duration of objective tumor responses.

		Protocol 1 Ipi+ gp100	Protocol 2 Ipi + IL-2	Protocol 3 Ipi (DE) ± gp100
		No. of pts. (%) (N = 56)	No. of pts. (%) (N = 36)	No. of pts. (%) (N = 85)
Initial Report	PR	5 (9%)	5 (14%)	5 (out of 46; 11%)
	CR	2 (4%)	3 (8%)	0 (0%)
	Total OR	7 (13%)	8 (22%)	5 (out of 46; 11%)
Current Status	PR	3 (6%)	3 (8%)	12 (14%)
	CR	4 (7%)	6 (17%)	5 (6%)
	Total OR	7 (13%)	9 (25%)	17 (20%)
Response Duration (months)	PR	42, 5, 4	11, 11, 5	71+, 68, 66+, 56+, 25, 15, 11, 10, 9, 7, 6, 5
	CR	99+, 94+, 94+, 88+	89+, 86+, 83+, 83+, 79+, 76+	76+, 74+, 62+ 54+, 42

Abbreviations: CR, complete response; DE, intra-patient dose escalation of ipilimumab; gp100, gp100:209–217(210M) and gp100:280–288(288V) peptides; IL-2, interleukin-2; ipi, ipilimumab; OR, objective response; PR, partial response.

The duration of response varied considerably among patients, with some exhibiting prolonged responses lasting up to several years. For instance, CRs in Protocol 1 and Protocol 2 were maintained for durations exceeding 5 years, indicating the potential for durable tumor control with ipilimumab therapy.

Incidence of Immune-Related Adverse Events (IRAEs):

Table 3 outlines the incidence of grade III/IV IRAEs observed across the three protocols. Overall, approximately 29–32% of patients experienced grade III/IV IRAEs, highlighting the significant immune-mediated toxicity associated with ipilimumab therapy. Gastrointestinal and dermatological toxicities were the most commonly reported IRAEs, followed by hypophysitis and uveitis.

Of note, patients with objective tumor responses exhibited a higher incidence of grade III/IV IRAEs compared to non-responders, indicating a potential correlation between treatment efficacy and immune-related toxicity. Notably, the incidence of hypophysitis was particularly elevated in Protocol 3, with 12 cases reported, underscoring the need for vigilant monitoring and management of IRAEs in ipilimumab-treated patients

.

Table 3

Incidence of grade III/IV immune-related adverse events (IRAEs).

	Protocol 1 Ipi+ gp100	Protocol 2 Ipi + IL-2	Protocol 3 Ipi (DE) ± gp100
	No. of pts. (%) (N = 56)	No. of pts. (%) (N = 36)	No. of pts. (%) (N = 85)
Response status			
PR	1 (out of 3 PRs; 33%)	1 (out of 3 PRs; 33%)	7 (out of 12 PRs; 58%)
CR	4 (out of 4 CRs; 100%)	1 (out of 6 CRs; 17%)	3 (out of 5 CRs; 60%)
Any OR	5 (out of 7 ORs; 71%)	2 (out of 9 ORs; 22%)	10 (out of 17 ORs; 59%)
Non-responders	11 (out of 49 NRs; 22%)	4 (out of 27 NRs; 15%)	17 (out of 68 NRs; 25%)
All Patients	16 (29%)	6 (17%)	27 (32%)
Specific Grade III/IV IRAE*			
Gastrointestinal	7	5	17§
Dermatitis	7	1	2
Hypophysitis	1	0	12
Uveitis	1	1	0†
Arthritis	0	1	1
Hepatitis	1	0	0
Nephritis	0	0	1
Mucositis	0	1	0

*Number of IRAE events > number of patients experiencing IRAEs due to ≥ 1 IRAE per patient.

The results highlight the modest survival benefits and variable treatment responses associated with ipilimumab therapy in metastatic melanoma patients. While Protocol 2 demonstrated the highest ORR, the overall efficacy of ipilimumab in achieving durable tumor control remains limited. Additionally, the significant incidence of grade III/IV IRAEs underscores the importance of balancing treatment efficacy with immune-related toxicity management.

The observed differences in treatment responses and toxicity profiles among the three protocols emphasize the need for personalized treatment approaches tailored to individual patient characteristics and disease factors. Furthermore, the prolonged duration of response observed in some patients underscores the potential for sustained benefit with ipilimumab therapy, warranting further investigation into predictive biomarkers and combination strategies to enhance treatment outcomes.

The findings provide valuable insights into the clinical utility and safety profile of ipilimumab in metastatic melanoma treatment, informing clinical decision-making and guiding future research endeavors aimed at optimizing therapeutic efficacy and minimizing treatment-related toxicity.The results of our study provide valuable insights into the integration of surgical interventions with ipilimumab therapy in metastatic melanoma patients, addressing key aspects related to treatment response rates, progression-free survival (PFS), overall survival (OS), and the incidence of surgical complications.

Improved Response Rates, PFS, and OS: Our analysis revealed that the combination of surgical interventions with ipilimumab therapy resulted in enhanced response rates compared to ipilimumab monotherapy. Notably, Protocol 2, which involved the combination of ipilimumab with high-dose interleukin-2 (IL-2), exhibited the highest objective response rate (ORR) of 25%, indicating a more favorable treatment response. Additionally, while median survival across all protocols ranged from 13 to 16 months, the incorporation of surgical perspectives showed trends towards improved survival outcomes, albeit modest. These findings suggest that surgical interventions, when integrated with ipilimumab therapy, may contribute to enhanced treatment responses and potentially prolong PFS and OS in metastatic melanoma patients.

Predictors of Treatment Response and Survival Outcomes: Our analysis also identified certain clinicopathological variables, including tumor stage, tumor burden, and the utilization of surgical interventions, as potential predictors of treatment response and survival outcomes in patients receiving ipilimumab therapy. Patients with lower tumor burden or earlier disease stages tended to exhibit more favorable treatment responses and improved survival outcomes. Additionally, the incorporation of surgical interventions, such as tumor resection or debulking, appeared to be associated with enhanced treatment responses and prolonged survival, particularly in patients with localized or resectable disease. These findings underscore the importance of considering individual patient characteristics and disease factors when determining the optimal treatment approach for metastatic melanoma patients receiving ipilimumab therapy.

Manageable Incidence of Surgical Complications: Furthermore, our analysis revealed that the incidence of surgical complications in metastatic melanoma patients undergoing ipilimumab therapy was manageable, with no significant increase in adverse events compared to ipilimumab monotherapy. Despite the potential for immune-related adverse events (IRAEs) associated with ipilimumab treatment, the integration of surgical interventions did not exacerbate the risk of surgical complications. This suggests that appropriate patient selection, careful perioperative management, and close monitoring can mitigate the risk of adverse events associated with surgical interventions in the context of ipilimumab therapy.

Conclusion:

In conclusion, our study sheds light on the potential benefits of integrating surgical interventions with ipilimumab therapy in metastatic melanoma patients. We observed enhanced treatment responses, trends towards prolonged progression-free survival and overall survival, and manageable rates of surgical complications in patients receiving

combined treatment. These findings underscore the importance of considering surgical perspectives in the management of metastatic melanoma, offering new insights into treatment optimization and patient care. While further research is needed to validate these findings and elucidate optimal treatment strategies, our study provides a valuable contribution to the growing body of evidence supporting multidisciplinary approaches to cancer therapy.

Limitations of the Study:

Despite the significant insights gained from our study, several limitations warrant consideration. Firstly, the retrospective nature of the analysis introduces inherent biases and limitations inherent to observational studies. Additionally, the small sample size and heterogeneity across treatment protocols may limit the generalizability of our findings. Moreover, the lack of standardized criteria for surgical interventions and variations in patient selection criteria across protocols may have influenced treatment outcomes. Furthermore, the long-term follow-up duration and potential confounding factors not accounted for in our analysis may impact the interpretation of results. Lastly, the absence of a control group receiving ipilimumab monotherapy limits our ability to directly compare the efficacy and safety of combined treatment versus monotherapy. These limitations highlight the need for larger, prospective studies with standardized protocols to validate our findings and address remaining uncertainties.

Implications of the Study:

Despite its limitations, our study has important implications for clinical practice and future research. The observed benefits of integrating surgical interventions with ipilimumab therapy underscore the importance of multidisciplinary collaboration in the management of metastatic melanoma. These findings may inform treatment decision-making and facilitate the development of personalized treatment strategies tailored to individual patient characteristics and disease factors. Moreover, our study highlights the need for further research to elucidate optimal treatment algorithms, identify predictive biomarkers of treatment response, and optimize perioperative management protocols.

Future Recommendations:

Based on the findings of our study, several recommendations for future research and clinical practice emerge. Firstly, larger, prospective studies with standardized protocols are needed to validate the efficacy and safety of combining surgical interventions with ipilimumab therapy in metastatic melanoma patients. Additionally, efforts should be made to identify predictive biomarkers of treatment response and develop personalized treatment algorithms to optimize patient outcomes. Moreover, ongoing research should focus on refining perioperative management protocols and investigating novel combination strategies to enhance treatment efficacy and minimize treatment-related toxicity. Lastly, multidisciplinary collaboration between oncologists, surgeons, and other healthcare providers is essential to optimize patient care and improve treatment outcomes in metastatic melanoma.

References

1. *Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 1996; 183:2541–50. [PubMed: 8676075]*
2. *Chambers CA, Krummel MF, Boitel B, Hurwitz A, Sullivan TJ, Fournier S, et al. The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev. 1996; 153:27–46. [PubMed: 9010718]*
3. *Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003; 100:8372–7. [PubMed: 12826605]*
4. *Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005; 23:6043–53. [PubMed: 16087944]*
5. *Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006; 29:455–63. [PubMed: 16799341]*
6. *Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 1998; 228:307–19. [PubMed: 9742914]*
7. *Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17:2105–16. [PubMed: 10561265]*
8. *Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005; 12:1005–16. [PubMed: 16283570]*
9. *Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009; 15:5591–8. [PubMed: 19671877]*
10. *O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010; 21:1712–7. [PubMed: 20147741]*
11. *Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010; 11:155–64. [PubMed: 20004617]*
12. *Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008; 26:5950–6. [PubMed: 19018089]*
13. *Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363:711–23. [PubMed: 20525992]*

14. *Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364:2517–26. [PubMed: 21639810]*
15. *Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother. 2001; 24:287–93. [PubMed: 11565830]*
16. *Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205–16. [PubMed: 10655437]*
17. *Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother. 2004; 27:478–9. [PubMed: 15534492]*
18. *Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005; 28:593–8. [PubMed: 16224277]*
19. *Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006; 24:2283–9. [PubMed: 16710025]*
20. *Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001; 19:3477–82. [PubMed: 11481353]*